Trump to Press China on Fentanyl Exports in Meeting With Xi

President Donald Trump plans to confront Chinese leader Xi Jinping over China’s role in the production and export of fentanyl and related synthetic opioids during their scheduled meeting next month, according to a senior Trump administration trade official. The issue, alongside China’s dominance in rare earth minerals, is expected to be a central focus of the bilateral summit, reflecting growing U.S. Concerns over Beijing’s involvement in the global illicit drug trade and strategic supply chains.

The official, speaking on condition of anonymity, said the Trump administration intends to press Beijing to curb the flow of precursor chemicals used to manufacture fentanyl, which are largely produced in China and shipped to Mexico and other countries where they are processed into the final drug. These chemicals have been linked to a surge in overdose deaths in the United States, where synthetic opioids now account for the majority of fatal overdoses.

Fentanyl, a synthetic opioid up to 50 times stronger than heroin, has driven a public health crisis in the U.S. Over the past decade. According to the Centers for Disease Control and Prevention, over 70,000 Americans died from synthetic opioid overdoses in 2023 alone, with fentanyl involved in the vast majority of those cases. U.S. Law enforcement and intelligence agencies have repeatedly identified Chinese chemical companies as key suppliers of the precursors needed to produce the drug, often exploiting regulatory gaps and using deceptive shipping practices to evade detection.

The upcoming Trump-Xi meeting, expected to take place in November 2025, will be one of the highest-level engagements between the two leaders since Trump returned to office. While the exact date and location have not been publicly confirmed, administration officials have indicated that trade, technology, and national security issues will dominate the agenda. The fentanyl issue adds a public health and law enforcement dimension to what is already a tense bilateral relationship marked by disputes over Taiwan, intellectual property, and market access.

In recent years, the U.S. Has taken steps to sanction Chinese entities and individuals implicated in the fentanyl supply chain. The Department of the Treasury has imposed sanctions on dozens of companies and nationals linked to the illicit chemical trade, while the Drug Enforcement Administration has increased cooperation with international partners to interdict shipments. However, Beijing has consistently denied state involvement in the trade, arguing that it enforces strict controls on chemical exports and cooperates with foreign authorities on a case-by-case basis.

China’s position on rare earths is also expected to feature prominently in the talks. The country controls approximately 70% of global rare earth mining and nearly 90% of processing capacity, giving it significant leverage over industries ranging from defense to renewable energy. The Trump administration has sought to reduce U.S. Dependence on Chinese rare earths through domestic mining incentives, recycling initiatives, and partnerships with allied nations, but progress has been slow.

Analysts note that linking fentanyl enforcement to broader trade and economic negotiations could provide the U.S. With additional leverage in its discussions with China. By tying cooperation on counternarcotics to market access or technology policies, the administration may aim to create incentives for Beijing to take stronger action against illicit chemical exporters. However, critics warn that such an approach risks oversimplifying a complex public health issue and may undermine efforts to treat addiction as a medical rather than purely criminal problem.

The Chinese government has not yet issued a public response to the reported agenda for the summit. Foreign Ministry spokespeople have previously emphasized China’s commitment to combating drug trafficking and have pointed to domestic laws regulating precursor chemicals. Nevertheless, U.S. Officials maintain that more needs to be done to close loopholes that allow illicit actors to operate with relative impunity.

As the meeting approaches, the Trump administration faces pressure from public health advocates, law enforcement groups, and members of Congress to deliver concrete outcomes on the fentanyl issue. Families affected by opioid addiction have called for stronger international action, while some policymakers argue that addressing the root causes of addiction — including demand reduction and treatment access — must accompany supply-side efforts.

For now, the upcoming summit represents a rare opportunity for direct high-level engagement between the two powers on a range of pressing global challenges. Whether the discussion will yield measurable progress on curbing fentanyl flows remains uncertain, but the inclusion of the issue on the agenda underscores its rising prominence in U.S. National security and foreign policy calculations.